TrialClinical pharmacokinetics2019

Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies.

Helena Edlund et al.PubMed ↗Publisher ↗

No numbers read from the abstract.